• Donate
  • Contact
Canadian Association of Pompe
  • Home
  • About Us
    • Personal Stories
    • Newsletter
  • About Pompe
  • Blog
  • Links
  • Connections
Select Page
Genzyme Study of Myozyme® for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints

Genzyme Study of Myozyme® for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints

by CAP | Dec 13, 2007 | Press Releases

Recent Posts

  • Audentes Therapeutics Pompe Program Update
  • Amicus Therapeutics Enters Research and Development Collaboration with University of Pennsylvania to Develop AAV Gene Therapies
  • Spark Therapeutics Announces New Preclinical Data for Their Pompe Disease Gene Therapy Candidate
  • Amicus Therapeutics Announces Positive 18-Month Data in Pompe Disease Phase 1/2 Study
  • Audentes Therapeutics program update for Pompe disease
  • Terms
  • Privacy

Copyright © 2006 - 2018 Canadian Association of Pompe | Developed by PacificByte